What is the 5K to Fight Histio?
The 5K to Fight Histio takes place each year at Hudson River Park in New York City. It started with under 200 registrants in 2013 after Liam's Lighthouse Foundation and its supporters wanted to expand their outreach and awareness during the time they spent together in New York City. In recent years, we reached over 510 registrants prior to race day! This 5K helps families from around the world gather together for a cause they hold close to their hearts while raising awareness and much needed funds for Histiocytosis at leading researching hospitals in the US.
Who’s ready for the 2021 5K To Fight Histio!
Join us virtually once again this year by registering your team and fundraising to support ground-breaking research! We are pleased to announce that proceeds from the event will go to help fund research initiatives at Cincinnati Children's Hospital (for LCH) and St. Jude's Children's Hospital (for HLH).
HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis run by Dr. Kim Nichols lab at St. Jude’s Children’s Research Hospital. This trial is based on our basic laboratory research and aims to test the efficacy of a new type of drug called a JAK inhibitor for children with HLH. JAK inhibitors suppress the pro-inflammatory effects of cytokines, and in so doing, they decrease the manifestations of HLH. Although we have some support from industry, we need more funding in order to complete the trial and carry out studies to better understand whether and how the JAK inhibitor mediates its effects in patients with HLH. For more details about this trial, please go HERE.
HISTIOTRAK: (run by Dr. Ashish Kumar’s Lab at Cincinnati Children’s Hospital.) A novel test to monitor minimal residual disease. Currently, once patients undergo treatment (chemotherapy or targeted inhibitor), the response to treatment is measured by scans – CT, PET, or MRI. Unfortunately, these are not sufficient to detect small amounts of residual cells that then cause disease relapse. We now know that all histiocytoses are driven by acquired mutations in one of the members of the MAP kinase pathway – most common being BRAF and MAP2K1. We can now detect rare histiocytic cells in blood by using a new sensitive method called droplet digital PCR (dd-PCR). However, this is currently still a research method. We are developing it into a clinical test, which requires us to run several (40-50) samples on it and demonstrate the consistency, sensitivity, and specificity. Funds are needed to generate these data that will be used to apply for certification by CAP (college of American pathologists).